Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866208 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL1702078 | 0.85 | LMNA (0.42) | POLBGAABRD4PKM | |
| SCHEMBL1700514 | 0.84 | BRD4 (0.37) | BRD4 | |
| SCHEMBL1958260 | 0.79 | ALDH1A1 (0.40) | KMT2AMEN1POLB | |
| SCHEMBL1700740 | 0.77 | KMO (0.46) | KMT2AMEN1POLBGAASMN1; SMN2 | |
| SCHEMBL1700744 | 0.77 | KMO (0.46) | KMT2AMEN1POLBGAASMN1; SMN2 | |
| SCHEMBL1700794 | 0.77 | P2RX4 (0.51) | KMT2AMEN1BRD4 | |
| SCHEMBL1868758 | 0.77 | BRD4 (0.37) | BRD4 | |
| SCHEMBL1863097 | 0.77 | MEN1 (0.46) | MGLLKMT2AMEN1POLBGAA | |
| SCHEMBL1810612 | 0.76 | SOS1 (0.45) | SOS1KMT2AMEN1SMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632436-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2613769-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012121758-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012058392-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |